LONDON--(BUSINESS WIRE)--Revenues in the European lung cancer therapeutics market are set to grow at an accelerated pace due to the anticipated launch of products currently in phase III of development and the recent introduction of targeted therapies. Pharmaceutical and biotech companies are investing significant amounts of money in R&D in this sector.
